ARTL Artelo Biosciences, Inc.
Listings ·
Artelo was among about 180 Nasdaq companies first identified as below the new threshold. The company gives no market value figure, and the rule is on a temporary stay.
Artelo will combine every nine shares of common stock into one, with split-adjusted trading beginning August 31, 2026, and about 547,774 shares outstanding afterward.
Nasdaq confirmed that Artelo Biosciences has regained compliance with its equity and annual meeting rules. The company is now subject to a one-year panel monitor.
Nasdaq's staff ruled that Artelo had not completed the capital raise it promised to fix its equity shortfall. Trading continues pending a hearing panel appeal, and the company's last annual report carried going-concern doubt.
R.F. Lafferty & Co., Inc. is the sole book-running manager. The filing also cuts the company's at-the-market program to $0 after it sold all the remaining stock under it.
MaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.
The May 22, 2025 letter cites Nasdaq Listing Rule 5550(b)(1). Artelo has until July 7, 2025 to submit a plan to regain compliance, and the stock stays listed in the meantime.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.4 million | $6.0 million |
| Net income (loss) | -$12.9 million | -$9.8 million |
| Cash from operations | -$8.5 million | -$8.3 million |
| Cash and equivalents | $600,000 | $2.3 million |
| Short-term investments | $0 |
Our latest story on this, dated Aug 27, 2026: "Artelo Biosciences sets 1-for-9 reverse split, trading from August 31, 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 25, 2025: "Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Nov 25, 2025: "Artelo Biosciences gets Nasdaq delisting determination over stockholders' equity, plans appeal". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Sep 30, 2025: "Artelo Biosciences prices $1,999,984.67 offering at $4.40 a share". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 11, 2025: "Artelo Biosciences' updated 2024 statements carry auditor going-concern doubt". The story links the filing or release it is based on. Read the story.
Artelo Biosciences, Inc. trades under the ticker ARTL on NASDAQ.
Artelo Biosciences, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Artelo Biosciences, Inc. is 1621221. Its filings are on SEC EDGAR.
4,595,068 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Artelo Biosciences, Inc. under United States.
Our directory classifies Artelo Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Artelo Biosciences, Inc. is US04301G8050.
aibio.space lists Artelo Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Artelo Biosciences, Inc. reported a net loss of $12.9 million for the fiscal year ended Dec 31, 2025, and used $8.5 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a financing. SEC Form 424B5. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 2.02,8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio